Compare AU
Compare INCM vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Income Leaders ETF (INCM) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
INCM | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 13 | 82 |
Median incremental investment | $1,293.46 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,763.40 | $1,323.41 |
Average age group | > 35 | > 35 |
Key Summary
INCM | CURE | |
|---|---|---|
Strategy | INCM.AX was created on 2018-10-18 by BetaShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The fund aims to track the performance of an index (before fees and expenses) that comprises 100 high-yielding global companies (ex-Australia) selected for their potential to generate attractive and sustainable income. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | ALTRIA GROUP INC (3.34 %) AT&T INC (2.08 %) VERIZON COMMUNICATIONS INC (1.92 %) | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) |
Top 3 industries | Other (30.45 %) Utilities (24.29 %) Consumer Staples (11.82 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (70.82 %) Korea (4.54 %) Hong Kong (3.66 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.45 % | 0.45 % |
Key Summary
INCM | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Global Income Leaders Index - USD-US Dollar | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.45 % |
Price | $18.68 | $49.94 |
Size | $36.712 million | $38.065 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.13 % | 4.24 % |
Market | ASX | ASX |
First listed date | 22/10/2018 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
INCM | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 13 | 82 |
Median incremental investment | $1,293.46 | $619.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $4,763.40 | $1,323.41 |
Average age group | > 35 | > 35 |
Pros and Cons
INCM | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
INCM | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |